dalteparin has been researched along with Cardiomyopathies, Primary in 2 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, JL | 1 |
| Tanhehco, EJ | 1 |
| Kilgore, KS | 1 |
| Gralinski, MR | 1 |
| Lucchesi, BR | 1 |
| Strobel, J | 1 |
| Schröder, S | 1 |
2 other studies available for dalteparin and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Reviparin-sodium prevents complement-mediated myocardial injury in the isolated rabbit heart.
Topics: Animals; Anticoagulants; Cardiomyopathies; Complement Activation; Complement C3 Convertase, Alternat | 1997 |
[Postpartum cardiomyopathy].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Anticoagula | 2011 |